Stock Market Reviews

NTRA (Natera, Inc.) News

Get the latest news, insights, and market updates on NTRA (Natera, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI
  AUSTIN, Texas, January 06, 2026--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that new data from the ALTAIR trial will be presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), taking place January 8-10, 2026.
  Jan 6, 2026 - $NTRA
• Natera Launches 21-Gene Fetal Focus™ Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP™ Technology
  AUSTIN, Texas, January 05, 2026--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of Natera’s expanded 21-gene Fetal Focus single gene non-invasive prenatal test (sgNIPT), supported by new findings from the blinded prospective EXPAND clinical trial. Results from this analysis demonstrate the test’s ability to detect a broader set of clinically relevant inherited conditions with high accuracy.
  Jan 5, 2026 - $NTRA
• Exploring 3 High Growth Tech Stocks In The US Market
  As the U.S. market rings in the new year with mixed performances across major indices, including a four-session skid to close out 2025, investors are closely watching the tech sector for signs of resilience and growth potential. In this environment, identifying high-growth tech stocks requires careful consideration of factors such as innovation capabilities and market adaptability, which can be crucial in navigating both challenges and opportunities presented by current economic conditions.
  Jan 2, 2026 - $NTRA
• Natera (NTRA) Announces Publication of Findings from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study
  Natera, Inc. (NASDAQ:NTRA) is one of the High Growth Large Cap Stocks to Buy Right Now. On December 18, the company announced publication of the findings from the randomized, phase III CALGB (Alliance)/SWOG 80702 study in JAMA Oncology. CALGB (Alliance)/SWOG 80702 assessed predictive value of postoperative personalized circulating tumor DNA (ctDNA) in patients having stage III colorectal […]
  Dec 31, 2025 - $NTRA
• Medical Stock Hovers Near Buy Point After 46% Gain
  Natera has yet to become profitable, but shares of the genetic testing and diagnostics company have run up nearly 50% this year, and funds have been loading up on the medical services stock. Natera reported its third-quarter results on Nov. 6, saying it lost 64 cents per share on sales that grew 35% to $592.2 million.
  Dec 30, 2025 - $NTRA
• 3 Growth Stocks with Explosive Upside
  Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who lost money in tech stocks during 2022.
  Dec 29, 2025 - $NTRA
• Is Natera’s 486% Three Year Surge Still Justified by Its Fundamentals?
  If you are wondering whether Natera's share price still makes sense after such a big run, you are not alone. This breakdown is designed to help you decide if the current price offers genuine value or just momentum. The stock has climbed about 47.0% over the last year and is up a hefty 486.4% over three years, even after a relatively flat last month with a 0.7% dip and a modest 1.5% gain in the past week. Much of this move has been driven by growing optimism around Natera's position in...
  Dec 26, 2025 - $NTRA
• Medical Stocks On The Move In Top Growth List As Health Sector Performance Brightens
  Medical stocks as a whole faced rough waters entering 2025, but market rotation is among the factors pushing up stock prices throughout the health industry as the year winds down. Such gains and other fundamental considerations have led medical companies like Guardant Health onto the IBD 50 list of top growth stocks. Others on the list include PACS Group, Natera and Nutex .
  Dec 26, 2025 - $NTRA
• 3 Reasons We’re Fans of Natera (NTRA)
  Over the past six months, Natera has been a great trade, beating the S&P 500 by 24.2%. Its stock price has climbed to $235.65, representing a healthy 37.1% increase. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
  Dec 24, 2025 - $NTRA
• J.P. Morgan Lifts Natera, Inc. (NTRA) Target on Signatera Momentum
  We recently compiled a list of the 7 Most Promising Gene Editing Stocks According to Analysts. Natera, Inc. stands fifth on our list among the most promising stocks. TheFly reported on December 15 that J.P. Morgan raised its price target on NTRA from $250 to $260 while maintaining an Overweight rating, reflecting confidence in the […]
  Dec 23, 2025 - $NTRA